Details of the Drug Reposition

General Information of This Drug (ID: DM9QF65)

Drug Name
GR-MD-02   DM9QF65
Synonyms Belapectin
Drug Type
Protein

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Melanoma DIS1RRCY 2C30 Phase 2 [1]
Hypertension DISLL965 BA00-BA04 Phase 2 [2]
Plaque psoriasis DISQX1LF EA90.0 Phase 2 [3]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-alcoholic steatohepatitis DIST4788 DB92.1 Phase 1 [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02462967) Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT01899859) Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. U.S. National Institutes of Health.